688765 禾元生物
已收盘 05-13 15:00:01
资讯
新帖
简况
禾元生物（688765）披露2025年度持续督导年度跟踪报告，5月13日股价上涨4.39%
证券之星 · 17:49
禾元生物（688765）披露2025年度持续督导年度跟踪报告，5月13日股价上涨4.39%
每周股票复盘：禾元生物（688765）将召开2025年报及2026Q1业绩说明会
证券之星 · 05-10
每周股票复盘：禾元生物（688765）将召开2025年报及2026Q1业绩说明会
每周股票复盘：禾元生物（688765）股东户数减少10.29%，一季报营收增132.39%
证券之星 · 05-02
每周股票复盘：禾元生物（688765）股东户数减少10.29%，一季报营收增132.39%
禾元生物（688765）2026年一季报简析：营收上升亏损收窄
证券之星 · 04-29
禾元生物（688765）2026年一季报简析：营收上升亏损收窄
4月28日禾元生物跌11.76%，华夏中证光伏产业ETF发起式联接A基金重仓该股
证券之星 · 04-28
4月28日禾元生物跌11.76%，华夏中证光伏产业ETF发起式联接A基金重仓该股
禾元生物（688765）530.13万股限售股将于4月28日解禁，占总股本1.48%
证券之星 · 04-28
禾元生物（688765）530.13万股限售股将于4月28日解禁，占总股本1.48%
图解禾元生物一季报：第一季度单季净利润同比增长25.21%
证券之星 · 04-28
图解禾元生物一季报：第一季度单季净利润同比增长25.21%
4月24日禾元生物创60日新低，华夏中证光伏产业ETF发起式联接A基金重仓该股
证券之星 · 04-24
4月24日禾元生物创60日新低，华夏中证光伏产业ETF发起式联接A基金重仓该股
每周股票复盘：禾元生物（688765）2025年净亏1.579亿元
证券之星 · 03-01
每周股票复盘：禾元生物（688765）2025年净亏1.579亿元
禾元生物：产线产能受多种因素影响
证券日报 · 02-27
禾元生物：产线产能受多种因素影响
禾元生物发布2025年度业绩快报，亏损1.579亿元
证券之星 · 02-26
禾元生物发布2025年度业绩快报，亏损1.579亿元
禾元生物：四年累亏超6亿，多风险交织下的“未盈利”样本
新浪证券 · 02-06
禾元生物：四年累亏超6亿，多风险交织下的“未盈利”样本
股市必读：禾元生物（688765）预计2025年全年扣除后营业收入:4,500万元至5,000万元
证券之星 · 01-29
股市必读：禾元生物（688765）预计2025年全年扣除后营业收入:4,500万元至5,000万元
禾元生物(688765.SH)：2025年预亏1.43亿元至1.67亿元
中金财经 · 01-28
禾元生物(688765.SH)：2025年预亏1.43亿元至1.67亿元
吉林敖东：公司暂无对禾元生物的投资计划
证券之星 · 01-26
吉林敖东：公司暂无对禾元生物的投资计划
贝达药业：投资禾元生物公允价值变动不影响净利润
证券之星 · 01-21
贝达药业：投资禾元生物公允价值变动不影响净利润
禾元生物（688765）披露关于持股5%以上股东部分股份质押的公告，12月17日股价上涨0.12%
证券之星 · 2025-12-17
禾元生物（688765）披露关于持股5%以上股东部分股份质押的公告，12月17日股价上涨0.12%
禾元生物（688765）公司公告披露购买董高责任险议案获股东会通过，12月12日股价下跌3.68%
证券之星 · 2025-12-12
禾元生物（688765）公司公告披露购买董高责任险议案获股东会通过，12月12日股价下跌3.68%
【机构调研记录】鹏扬基金调研禾元生物
证券之星 · 2025-12-02
【机构调研记录】鹏扬基金调研禾元生物
卫光生物：暂未与禾元生物开展合作
证券之星 · 2025-11-17
卫光生物：暂未与禾元生物开展合作
加载更多
公司概况
公司名称：
武汉禾元生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2025-10-28
主营业务：
武汉禾元生物科技股份有限公司的主营业务是运用水稻胚乳细胞重组蛋白表达技术平台进行植物源人血清白蛋白等产品的研发、生产及销售。公司的主要产品是已上市药品、正在开展临床或临床前试验的药品、已经登记的药用辅料、科研试剂产品。公司2013年获得国家技术发明奖。
发行价格：
29.06
{"stockData":{"symbol":"688765","market":"SH","secType":"STK","nameCN":"禾元生物","latestPrice":61.8,"timestamp":1778655601000,"preClose":59.2,"halted":0,"volume":3572026,"delay":0,"changeRate":0.0439,"floatShares":46280000,"shares":358000000,"eps":-0.4053,"marketStatus":"已收盘","change":2.6,"latestTime":"05-13 15:00:01","open":59.99,"high":62.5,"low":58.18,"amount":216000000,"amplitude":0.073,"askPrice":61.81,"askSize":7,"bidPrice":61.8,"bidSize":6,"shortable":0,"etf":0,"ttmEps":-0.4053,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778722200000},"marketStatusCode":5,"adr":0,"adjPreClose":59.2,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778635800000,1778643000000],[1778648400000,1778655600000]],"highLimit":65.12,"lowLimit":53.28,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":357500000,"isCdr":false,"pbRate":7.7,"roa":"--","roe":"--","epsLYR":-0.555,"committee":-0.27907,"marketValue":22094000000,"turnoverRate":0.0772,"status":0,"afterMarket":{"amount":12360,"volume":200,"close":61.8,"buyVolume":200,"sellVolume":0,"time":1778657637558,"indexStatus":"已收盘 05-13 15:30:00","preClose":59.2},"floatMarketCap":2860000000},"requestUrl":"/m/hq/s/688765","defaultTab":"news","newsList":[{"id":"2635200600","title":"禾元生物（688765）披露2025年度持续督导年度跟踪报告，5月13日股价上涨4.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200600","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635200600?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:49","pubTimestamp":1778665789,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，禾元生物报收于61.8元，较前一交易日上涨4.39%，最新总市值为220.94亿元。该股当日开盘59.99元，最高62.5元，最低58.18元，成交额达2.16亿元，换手率为7.72%。禾元生物于近日披露《国泰海通证券股份有限公司关于武汉禾元生物科技股份有限公司2025年度持续督导年度跟踪报告》。2025年7月，公司首个创新药奥福民获批上市，为国内首个重组人白蛋白药品。报告期内营业收入同比增长89.80%，主要来自奥福民销售。研发投入9266.06万元，同比有所下降。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634228414","title":"每周股票复盘：禾元生物（688765）将召开2025年报及2026Q1业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2634228414","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634228414?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:53","pubTimestamp":1778352788,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，禾元生物报收于58.02元，较上周的55.07元上涨5.36%。本周，禾元生物5月8日盘中最高价报58.22元。5月6日盘中最低价报54.79元。禾元生物当前最新总市值207.42亿元，在生物制品板块市值排名14/51，在两市A股市值排名1079/5200。本周关注点公司公告汇总：禾元生物将于2026年5月13日召开2025年年度暨2026年第一季度业绩说明会。说明会后可通过该网站查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632862353","title":"每周股票复盘：禾元生物（688765）股东户数减少10.29%，一季报营收增132.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632862353","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632862353?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:56","pubTimestamp":1777672572,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，禾元生物报收于55.07元，较上周的59.88元下跌8.03%。本周，禾元生物4月27日盘中最高价报60.78元。本周关注点股本股东变化：股东户数较12月31日减少10.29%，户均持股增至2.13万股。业绩披露要点：2026年一季报主营收入962.81万元，同比上升132.39%。股本股东变化股东户数变动截至2026年3月31日，禾元生物股东户数为1.68万户，较12月31日减少1926.0户，减幅10.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631310558","title":"禾元生物（688765）2026年一季报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2631310558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631310558?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:56","pubTimestamp":1777420576,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期禾元生物发布2026年一季报。根据财报显示，禾元生物营收上升亏损收窄。截至本报告期末，公司营业总收入962.81万元，同比上升132.39%，归母净利润-3604.59万元，同比上升25.21%。本次财报公布的各项数据指标表现尚佳。），公司上市来已有年报1份，亏损年份1次，需要仔细研究下有无特殊原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900024397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630757773","title":"4月28日禾元生物跌11.76%，华夏中证光伏产业ETF发起式联接A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630757773","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630757773?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:28","pubTimestamp":1777364898,"startTime":"0","endTime":"0","summary":"证券之星消息，4月28日禾元生物跌11.76%创60日新低，收盘报53.33元，换手率13.96%，成交量6.46万手，成交额3.56亿元。重仓禾元生物的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华夏基金的华夏中证光伏产业ETF发起式联接A。华夏中证光伏产业ETF发起式联接A目前规模为3.66亿元，最新净值0.6679，较上一交易日下跌0.83%，近一年上涨61.72%。该公募基金现任基金经理为李俊。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800049136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159863","688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630334901","title":"禾元生物（688765）530.13万股限售股将于4月28日解禁，占总股本1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630334901","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630334901?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:05","pubTimestamp":1777334705,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，禾元生物于4月28日将有530.13万股限售股份解禁，为公司首发机构配售股份，占公司总股本1.48%。本次解禁后，公司还有3.11亿股限售股份，占总股本87.05%。禾元生物主营业务：植物分子医药的研发、生产及商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800026636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630931253","title":"图解禾元生物一季报：第一季度单季净利润同比增长25.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630931253","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630931253?lang=zh_cn&edition=full","pubTime":"2026-04-28 03:40","pubTimestamp":1777318825,"startTime":"0","endTime":"0","summary":"证券之星消息，禾元生物2026年一季报显示，一季度公司主营收入962.81万元，同比上升132.39%；归母净利润-3604.59万元，同比上升25.21%；扣非净利润-4076.07万元，同比上升16.49%；负债率21.22%，投资收益428.03万元，财务费用12.69万元，毛利率42.04%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800010556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629294816","title":"4月24日禾元生物创60日新低，华夏中证光伏产业ETF发起式联接A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629294816","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629294816?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:29","pubTimestamp":1777019380,"startTime":"0","endTime":"0","summary":"证券之星消息，4月24日禾元生物创60日新低，收盘报59.88元，当日跌3.19%，换手率2.86%，成交量1.17万手，成交额7111.4万元。重仓禾元生物的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华夏基金的华夏中证光伏产业ETF发起式联接A。华夏中证光伏产业ETF发起式联接A目前规模为3.66亿元，最新净值0.6834，较上一交易日下跌0.5%，近一年上涨65.07%。该公募基金现任基金经理为李俊。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400050033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159863","BK0239","688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843155","title":"每周股票复盘：禾元生物（688765）2025年净亏1.579亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843155","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843155?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:07","pubTimestamp":1772302031,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，禾元生物报收于73.09元，较上周的72.04元上涨1.46%。本周，禾元生物2月27日盘中最高价报75.5元。禾元生物当前最新总市值261.3亿元，在生物制品板块市值排名13/51，在两市A股市值排名848/5189。本周关注点来自业绩披露要点：禾元生物2025年归属净利润亏损1.579亿元，同比减少4.34%。公司公告汇总武汉禾元生物科技股份有限公司发布2025年度业绩快报，营业总收入4,786.14万元，同比增长89.80%；归属于母公司所有者的净利润为-15,794.49万元，亏损同比增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614085245","title":"禾元生物：产线产能受多种因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085245","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614085245?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:04","pubTimestamp":1772201040,"startTime":"0","endTime":"0","summary":"证券日报网讯 2月27日，禾元生物在互动平台回答投资者提问时表示，产线产能受多种因素影响，其中由于蛋白表达量的增加，产能和收率均会有提升，但不会呈现倍数对应关系，主要受产品得收率和层析填料载量等限制因素的影响，具体产能提升程度要依据实际数据而定。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-27/doc-inhphqpa3498354.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-27/doc-inhphqpa3498354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688765","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614315016","title":"禾元生物发布2025年度业绩快报，亏损1.579亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614315016","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614315016?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:12","pubTimestamp":1772097133,"startTime":"0","endTime":"0","summary":"证券之星消息，禾元生物近日即将发布2025年年报，根据2月26日发布的业绩快报，归属净利润亏损1.579亿元，同比减少4.34%。报告期末，公司总资产 370,198.08 万元，较期初增长 248.65%；归属于母公司的所有者权益 289,698.35 万元，较期初增长 381.75%。于2025 年 7 月获批上市后快速实现销售突破，随着市场推广的持续深入以及终端用户对产品临床价值认可度的不断提升，为公司发展提供增长动力。禾元生物主营业务：植物分子医药的研发、生产及商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600025671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609568129","title":"禾元生物：四年累亏超6亿，多风险交织下的“未盈利”样本","url":"https://stock-news.laohu8.com/highlight/detail?id=2609568129","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609568129?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:13","pubTimestamp":1770365580,"startTime":"0","endTime":"0","summary":" 作为一家通过科创板第五套上市标准登陆资本市场的未盈利生物医药企业，禾元生物自上市以来便备受关注。然而，随着近期公司发布2025年业绩预告，其持续扩大的亏损、紧绷的现金流、核心产品商业化存疑以及信息披露的争议，正使其成为观察未盈利科创企业生存现状的一个典型样本。 禾元生物近日披露，预计2025年归母净利润亏损1.43亿元至1.67亿元，加上此前三年累计亏损已超4.8亿元，这意味着公司四年来累计亏损将突破6亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-02-06/doc-inhkwnki2086633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688765","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607746969","title":"股市必读：禾元生物（688765）预计2025年全年扣除后营业收入:4,500万元至5,000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607746969","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607746969?lang=zh_cn&edition=full","pubTime":"2026-01-29 01:06","pubTimestamp":1769619972,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘，禾元生物报收于79.6元，下跌4.1%，换手率5.81%，成交量2.38万手，成交额1.93亿元。业绩披露要点业绩预告禾元生物发布业绩预告，预计2025年全年归属净利润亏损1.43亿元至1.67亿元；预计全年营业收入为4500万元至5000万元，同比增长78.46%至98.29%；扣除后营业收入为4,500万元至5,000万元；扣非后净利润预计亏损1.62亿元至1.91亿元。预计2025年年度实现营业收入4,500万元到5,000万元，同比增长78.46%到98.29%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900000741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606969267","title":"禾元生物(688765.SH)：2025年预亏1.43亿元至1.67亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606969267","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606969267?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:37","pubTimestamp":1769589422,"startTime":"0","endTime":"0","summary":"格隆汇1月28日丨禾元生物公布，经财务部门初步测算，预计2025年年度实现利润总额-16,700万元到-14,300万元，预计2025年年度实现归属于母公司所有者的净利润-16,700万元到-14,300万元。预计2025年年度实现营业收入4,500万元到5,000万元，同比增加78.46%到98.29%，扣除与主营业务无关的业务收入和不具备商业实质的收入后的营业收入为4,500万元到5,000万元。受上述因素共同影响，报告期内公司整体仍处于业绩亏损状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260128/31979451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688765","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606929764","title":"吉林敖东：公司暂无对禾元生物的投资计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2606929764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606929764?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:45","pubTimestamp":1769413518,"startTime":"0","endTime":"0","summary":"证券之星消息，吉林敖东01月26日在投资者关系平台上答复投资者关心的问题。或者是继续加大对辽宁成大的投资计划？谢谢吉林敖东回复：尊敬的投资者：您好！公司暂无对禾元生物的投资计划。截至目前，公司及子公司延边药业合计持有辽宁成大103,625,476股，占辽宁成大总股本的6.77%，后续若有达到信息披露标准的事项将及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600015104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0074","688765","BK0028","BK0239","BK0012","BK0201","000623","BK0086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605580127","title":"贝达药业：投资禾元生物公允价值变动不影响净利润","url":"https://stock-news.laohu8.com/highlight/detail?id=2605580127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605580127?lang=zh_cn&edition=full","pubTime":"2026-01-21 12:33","pubTimestamp":1768969988,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)01月21日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘 我司投资的禾元生物，按最近禾元生物市值，权益法计算，对我司净利润将带来20-25亿的增加。请问如果按权益法计算，我司净利润将暴增700％。为什么我司还不发布业绩预告？贝达药业回复：您好！公司对武汉禾元生物科技股份有限公司的投资计入其他权益工具投资科目核算，根据企业会计准则有关规定，将其公允价值变动计入其他综合收益科目，不影响公司净利润。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100017326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592915894","title":"禾元生物（688765）披露关于持股5%以上股东部分股份质押的公告，12月17日股价上涨0.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915894","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592915894?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:04","pubTimestamp":1765980262,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，禾元生物报收于72.09元，较前一交易日上涨0.12%，最新总市值为257.72亿元。该股当日开盘71.95元，最高72.4元，最低70.57元，成交额达1.44亿元，换手率为4.91%。公司近日发布公告称，持股5%以上的股东上海同盛永盈企业管理中心持有公司股份20,084,400股，占公司总股本的5.62%。本次质押股份11,730,000股，占其持股总数的58.40%，占公司总股本的3.28%。质押股份为限售股，质权人为湖北省铁路发展基金有限责任公司，质押融资用于自身资金需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700038978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590850425","title":"禾元生物（688765）公司公告披露购买董高责任险议案获股东会通过，12月12日股价下跌3.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590850425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590850425?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:03","pubTimestamp":1765548220,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，禾元生物报收于77.54元，较前一交易日下跌3.68%，最新总市值为277.21亿元。近日，武汉禾元生物科技股份有限公司召开2025年第三次临时股东会，会议审议通过了《关于购买董高责任险的议案》。公告显示，出席会议的股东及代理人共655人，代表有表决权股份110,750,139股，占公司总表决权股份的34.9133%。该议案为普通决议议案，已获得出席股东所持有效表决权过半数通过，关联股东杨代常回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200040550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688765","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588701460","title":"【机构调研记录】鹏扬基金调研禾元生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701460?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:05","pubTimestamp":1764633942,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及12月1日披露的机构调研信息，鹏扬基金近期对1家上市公司进行了调研，相关名单如下：1）禾元生物 调研纪要：公司计划开展HY1001全球多中心III期临床，拓展至人血白蛋白全部适应症，并拟申报中美欧上市。鹏扬基金成立于2016年，截至目前，资产管理规模1453.24亿元，排名49/211；资产管理规模1249.96亿元，排名41/211；管理公募基金数183只，排名39/211；旗下公募基金经理26人，排名53/211。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200003778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584664899","title":"卫光生物：暂未与禾元生物开展合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2584664899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584664899?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:18","pubTimestamp":1763367501,"startTime":"0","endTime":"0","summary":"证券之星消息，卫光生物11月17日在投资者关系平台上答复投资者关心的问题。公司未来在利用动植物大规模生产重组人白蛋白有哪些布局？公司目前暂未与禾元生物开展合作，公司聚焦血液制品领域，坚持技术驱动产品研发，对新技术秉持开放拥抱态度，并密切关注市场动态和行业前沿技术与应用，不断提高自身综合竞争实力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700019970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002880","688765","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778687937074,"stockEarnings":[{"period":"1week","weight":0.075},{"period":"1month","weight":-0.097},{"period":"3month","weight":-0.1992},{"period":"6month","weight":-0.3075},{"period":"1year","weight":1.0372},{"period":"ytd","weight":-0.1434}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0573},{"period":"3month","weight":0.02},{"period":"6month","weight":0.0459},{"period":"1year","weight":0.2509},{"period":"ytd","weight":0.0619}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"武汉禾元生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"16797人(较上一季度减少10.29%)","perCapita":"2755股","listingDate":"2025-10-28","address":"湖北省武汉市江夏区武汉东湖新技术开发区神墩五路268号","registeredCapital":"35750万元","survey":" 武汉禾元生物科技股份有限公司的主营业务是运用水稻胚乳细胞重组蛋白表达技术平台进行植物源人血清白蛋白等产品的研发、生产及销售。公司的主要产品是已上市药品、正在开展临床或临床前试验的药品、已经登记的药用辅料、科研试剂产品。公司2013年获得国家技术发明奖。","listedPrice":29.06},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"禾元生物(688765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供禾元生物(688765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"禾元生物,688765,禾元生物股票,禾元生物股票老虎,禾元生物股票老虎国际,禾元生物行情,禾元生物股票行情,禾元生物股价,禾元生物股市,禾元生物股票价格,禾元生物股票交易,禾元生物股票购买,禾元生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"禾元生物(688765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供禾元生物(688765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}